摘要 |
<p>Compounds of formula (I) wherein: R1, R2, R3, R4, R5, R6, R7 and R8 are, independently, hydrogen, COOR15, halogen, nitro, cyano, C1-10 alkoxy, C1-10 haloalkoxy, sulfonic acid, C1-10 alkylsulfonyl, C6-12 arylsulfonyl, C6-12 aralkylsulfonyl, C1-10 alkylsulfinyl, C6-12 arylsufinyl, C6-12 aralkylsulfinyl, sulfamoyl, C1-10 alkylsulfamido, C6-12 arylsulfamido, C1-10 alkanoyl, C6-12 aryloyl, C6-12 aralkanoyl, amino, C1-10 alkylamino, C2-10 dialkylamino, C6-12 arakylamino, C6-12 arylamino, carboxamido, C1-10 alkylcarboxamido, C6-12 arylcarboxamido, C1-10 haloalkyl, C1-10 alkyl, C2-12 alkenyl, C6-12 aryl, C6-12 aralkyl; with the proviso that at least one of R4 and R5 is COOR15; R9 is hydrogen, C1-10 alkyl, and C1-10 haloalkyl; R10 is hydrogen, C1-10 alkyl, C1-10 haloalkyl, or C2-12 alkylidene; R15 is hydrogen, metal cation, acetylamido, alkoxyacetoyl or a related moiety which delivers the carboxylate in vivo; the dotted line is an optional double bond; with the proviso that when R10 is an alkylidene moiety, the double bond is absent; and W is nitrogen or carbon bearing a hydrogen, or R4, R5 or R6 as hereinbefore defined; or pharmaceutical salts thereof, are useful in the treatment of disorders associated with smooth muscle contraction via potassium channel and chloride channel modulation.</p> |